Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

It would have been impossible to predict then that she'd become instrumental in the development of the popular class of injectable diabetes and weight loss drugs like Ozempic and Wegovy that have ...

It was her research and development of Novo Nordisk's first daily GLP-1 shot for diabetes (liraglutide, approved in the US in 2010) that would spur the development of those more powerful ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

INDIANAPOLIS (WISH) — A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose weight. While these drugs are becoming wildly ...

Specifically, she focused her research on injectable peptides ... her teams at Novo Nordisk invented an entirely new class of diabetes and weight loss drugs, she's still level-headed about ...

Sol-Millennium® Medical Group, a leading manufacturer of medical devices, has launched an innovative needle-free injection ...